Printer Friendly

UCB SELLS OTC DELSYM TO ADAMS RESPIRATORY THERAPEUTICS.

UCB S.A., Brussels, Belgium, has reached an agreement with Adams Respiratory Therapeutics Inc. (NASDAQ: ARxT) to sell Delsym (dextromethorphan polistirex), an over-the-counter (OTC) 12-hour liquid cough suppressant. In addition, the two companies have entered into a separate agreement for the licensing of the 12-hour liquid technology.

The financial terms of the agreement consist of a one-time, upfront payment to UCB of 122 million U.S. dollars, royalties for a period of 5 years based on sales and a standard manufacturing supply agreement with a "cost-plus" structure.

"This transaction is another step taken by UCB in its strategy to focus on research-driven innovation and novel therapeutic solutions for severe and chronic diseases treated by specialist physicians," declared Roch Doliveux, CEO of UCB.

About Delsym

Delsym is a cough medicine that doctors and pharmacists have recommended for years in the United States. It is the only OTC liquid cough suppressant than can deliver 12 hours of cough relief in a single dose. Delsym is made with a patented time-release formulation that allows the cough suppressant dextromethorphan to be available in the body over a 12-hour period.

About Adams Respiratory Therapeutics, Inc.

Adams is a U.S.-based specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over- the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

For more information, visit http://www.adamsrt.com.

About UCB

UCB is a global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing 8,500 people in 40 countries, UCB achieved revenues of EUR2.3 billion in 2005. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters are located in Brussels, Belgium.

For more information, visit http://www.ucb-group.com.
COPYRIGHT 2006 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:4EUBL
Date:Jul 1, 2006
Words:315
Previous Article:UCB COMPLETES MUTUAL RECOGNITION PROCEDURE FOR EQUASYM XL.
Next Article:LABOPHARM GRANTS TRAMDOL MARKETING RIGHTS TO PURDUE PHARMA.
Topics:


Related Articles
INCLONE/UCB TO DEVELOP/COMMERCIALIZE CDP-791.
UCB LICENSES SEPRACOR U.S. PATENTS FOR ANTIHISTAMINE.
UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES.
Two-building complex a sure thing for investor.
Office building a no-risk investment for purchaser.
UCB INITIATES ADDITIONAL SHORT-TERM CLINICAL STUDY OF CIMZIA.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters